BioXcel Therapeutics (BTAI) Operating Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) posted Operating Margin of 5600.55% for Q2 2026, down 12.85% on a QoQ basis from 4962.62% in Q1 2026, and up 760945.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Operating Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics has reported Operating Margin for 5 years, with the latest figure at 5600.55% in Q2 2026.
- On a quarterly basis, Operating Margin rose 760945.0% year-over-year to 5600.55% in Q2 2026; TTM through Jun 2026 was 6054.72%, a 9423.0% decrease from a year earlier, with the FY2025 full-year figure at 7859.97%, down 489240.0% from the prior year.
- Operating Margin was 5600.55% for Q2 2026 at BioXcel Therapeutics, down from 4962.62% in the prior quarter.
- The five-year high for Operating Margin was 1566.67% in Q2 2024, with the low at 28459.85% in Q3 2022.
- Average Operating Margin over 5 years is 10656.68%, with a median of 6578.79% recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 2070168 bps in 2024, then plunged 1164333 bps in 2025.
- Over 5 years, Operating Margin stood at 22224.37% in 2022, then jumped by 76 bps to 5285.9% in 2023, then surged by 46 bps to 2866.94% in 2024, then plunged by 40 bps to 4016.41% in 2025, then slumped by 39 bps to 5600.55% in 2026.
- The last three Operating Margin figures came in at 5600.55% (Q2 2026), 4962.62% (Q1 2026), and 4016.41% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | -25,380.93% |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | -5,600.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,600.55% |
| Mar 31, 2026 | -4,962.62% |
| Dec 31, 2025 | -4,016.41% |
| Sep 30, 2025 | -14,518.37% |
| Jun 30, 2025 | -13,210.00% |
| Mar 31, 2025 | -6,011.31% |
| Dec 31, 2024 | -2,866.94% |
| Sep 30, 2024 | -7,146.26% |
| Jun 30, 2024 | -1,566.67% |
| Mar 31, 2024 | -4,151.72% |
| Dec 31, 2023 | -5,285.90% |
| Sep 30, 2023 | -14,163.34% |
| Jun 30, 2023 | -11,469.15% |
| Mar 31, 2023 | -24,853.40% |
| Dec 31, 2022 | -22,224.37% |
| Sep 30, 2022 | -28,459.85% |